Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy

Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Ding, Xiao-Xiao, Zhu, Qing-Ge, Zhang, Shi-Ming, Guan, Lei, Li, Ting, Zhang, Lei, Wang, Shi-Yang, Ren, Wan-Li, Chen, Xue-Mei, Zhao, Jing, Lin, Song, Liu, Zhi-Zhen, Bai, Yan-Xia, He, Bing, Zhang, Hu-Qin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589693/
https://ncbi.nlm.nih.gov/pubmed/28903454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18382
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia